Narcolepsy Drug Orzeyful Demonstrates Positive Phase 3 Trial Outcomes

New drug Orzeyful (oveporexton) demonstrated promising results in two Phase 3 clinical trials for narcolepsy type 1, as published in The New England Journal of Medicine. The orexin receptor activator significantly improved patients' ability to stay awake, offering a potential new treatment option for the condition. Common side effects included increased urinary frequency and transient insomnia.